NCT03495323: A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

NCT03495323
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Participants with known untreated unstable brain metastases or carcinomatous meningitis that require treatment- see trial for details; Patients who have received more than 4 lines of cytotoxic chemotherapy and/or prior CHK1 inhibitor therapy
https://ClinicalTrials.gov/show/NCT03495323

Comments are closed.

Up ↑